Behavioral improvement in MPTP-treated nonhuman primates in the HALLWAY task after transfer of TH cDNA to host astrocytes

• Autorzy: Campos-Romo A. , Ojeda-Flores R. , Moreno-Briseno P. , Vergara P. , Segovia J. , Carrillo-Ruiz J. D. , Fernandez-Ruiz J.
• Języki publikacji: EN

Abstrakty

EN

Parkinson's disease is a neurodegenerative disease, resulting from deterioration of the substantia nigra which in turn leads to a decrease of dopamine levels in the striatum. Clinically the syndrome is characterized by motor alterations that are treated by the oral administration of levodopa. However, this treatment typically loses efficacy over time and therefore new treatments that procure a steady long term supplement of dopamine are needed. Here we tested the expression of a tyrosine hydroxilase (TH) transgene in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primates own astrocytes. The transgene, whose expression of TH cDNA was controlled by a glial fibrillary acidic protein (GFAP) promoter, was injected into MPTP treated primate's brains using liposomes as a delivery system. Monkeys were tested before and after MPTP administration, and after gene therapy treatment on the HALLWAY behavioral task. Results showed both transgene expression and significant behavioral improvements in the hallway task after the TH cDNA transfer. The behavioral recovery observed in the primates whose astrocytes expressed rat TH, is a first step that warrant further studies using primate's astrocytes as a good cell lineage to express therapeutic molecules.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2012
• Tom: 72
• Numer: 2
• Opis fizyczny: p.166-176,fig.,ref.

Twórcy

autor

Campos-Romo A.

• Department of Physiology, Faculty of Medicine, National Autonomus University of Mexico, Mexico City, Mexico

autor

Ojeda-Flores R.

• Department of Physiology, Faculty of Medicine, National Autonomus University of Mexico, Mexico City, Mexico

autor

Moreno-Briseno P.

• Department of Physiology, Faculty of Medicine, National Autonomus University of Mexico, Mexico City, Mexico

autor

Vergara P.

• Department of Physiology, Biophysics and Neuroscience, Center of Research and Advanced Studies, IPN, Mexico City, Mexico

autor

Segovia J.

• Department of Physiology, Biophysics and Neuroscience, Center of Research and Advanced Studies, IPN, Mexico City, Mexico

autor

Carrillo-Ruiz J. D.

• Stereotaxic and Functional Neurosurgery Unit, Mexico General Hospital, SSA, Mexico
• Neuroscience and Psychophysiology Laboratory, School of Psychology, Anahuac University of North Mexico, Huixquilucan, Estado de Mexico, Mexico

autor

Fernandez-Ruiz J.

• Department of Physiology, Faculty of Medicine, National Autonomus University of Mexico, Mexico City, Mexico

Bibliografia

• Ahlskog JE, Muenter MD (2001) Frequency of levodoparealted dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16: 448¬458.
• Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J (2000) Convection-enhanced delivery of AAV vector in parkinsonian monkeys: in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164: 2-14.
• Bankiewicz KS, Forsayeth J, Eberling JL, Sanchez-Pernaute R, Pivirotto P, Bringas J (2006) Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14: 564-570.
• Benitez JA, Arregui L, Vergara P, Segovia J (2007) Targeted-simultaneous expression of Gas1 and p53 using a bicistronic adenoviral vector in gliomas. Cancer Gene Ther 14: 836-846.
• Brenner M, Kisseberth WC, Su Y, Besnard F, Mesing A (1994) GFAP promoter directs astrocyte-specific expres¬sion in transgenic mice. J Neurosci 14: 1030-1037.
• Burns RS, Kelly E, Reavill C, Jenner P, Marsden CD (1984) Repeated administration of n-methyl-4-phenyl-1,2,3,6- tetrahydropyridine to rats is not toxic to striatal dop- amine neurons. Biochem Pharmacol 33: 1747-1752.
• Burns RS, LeWitt PA, Ebert MH, Pakkenberg H, Kopin IJ (1985) The clinical syndrome of striatal dopamine defi¬ciency: parkinsomism by 1-methyl-4-phenyl-1,2,3,6-tet- rahydropyridine (MPTP). N Eng J Med 312: 1418-1421.
• Campos-Romo A, Ojeda-Flores R, Moreno-Briseño P, Fernández-Ruiz J (2009) Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the HALLWAY task. J Neurosci Meth 177: 361-368.
• Cortez N, Trejo F, Vergara P, Segovia J (2000) Primary astrocytes retrovirally transduced with a tyrosine hydroxylase transgene driven by a glial-specific promoter elicit behavioral recovery in experimental parkinsonism. J Neurosci 59: 39-46.
• De la Monte SM, Wells SE, Hedley-Whyte T, Growdon JH (1989) Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease. Ann Neurol 26: 309-320.
• Di Paolo T, Bedard P, Daigle M, Boucher R (1986) Long- term effects of MPTP on central and peripheal cate¬cholamine and indoleamine concentrations in monkeys. Brain Res 379: 286-293.
• Domínguez-Monzón G, Benítez JA, Vergara P, Lorenzana R, Segovia J (2009) Gas1 inhibits cell proliferation and induces apoptosis of human primary gliomas in the absence of Shh. Int J Develop Neurosci 27: 305-313.
• During MJ, Naegele JR, O'Malley KL (1994) Long-term behavioral recovery in parkinsonian rats by an HSV vec¬tor expressing tyrosine hydroxylase. Science 266: 1399¬1403.
• Eberling JL, Kells AP, Pivirotto P, Beyer J, Bringas J, Federoff HJ (2009) Functional Effects of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Parkinsonian Rhesus Monkeys. Hum Gene Ther 20: 511-518.
• Elsworth JD, Deutch AY, Redmond JDE, Taylor JR, Sladek JR, Roth RH (1989) Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions. Neuroscience 33: 323-331.
• Elsworth JD, Brittan MS, Taylor JR, Sladek JRJr, Redmond DEJr, Innis RB (1998) Upregulation of striatal D2 recep¬tors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradio¬graphic study. Brain Res 795: 55-62.
• Elsworth JD, Taylor JR, Sladek JRJr, Collier TJ, Redmond DEJR, Roth RH (2000) Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old- world primates one year after MPTP treatment. Neuroscience 95: 399-408.
• Emborg ME, Carbon M, Holden JE, During MJ, Ma Y, Tang C (2007) Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 27: 501-509.
• Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C (2005) Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neu¬roprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 25: 769 -777.
• Fernández-Ruiz J, Doudet DJ, Aigner TG (1995) Long term cognitive impairment in MPTP treated rhesus monkeys. Neuroreport 7: 102-104.
• Fernández-Ruiz J, Doudet D, Aigner TG (1999) Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys. Psychopharmacology (Berl) 147: 104-107.
• Forno LS, Delanney LE, Irwin I, Di Monte D, Langston JW (1992) Astrocytes and Parkinon disease. Prog Brain Res 94: 429-436.
• Freed CR, Greene PE, Brezze RE, Tsai WY, DuMouchel W, Kao R (2001) Transplantation of embryonyc dopamine neurons for severe Parkinson's Disease. N Engl J Med 344: 710-719.
• Fuente-Fernandez R, Calne DB (2002) Evidence for envi¬ronmental causation of Parkinson's disease Parkinsonism Relat Disord 8: 235-241.
• Galou M, Pournin S, Ensergueix D, Ridet JL, Tchélingérain JL, Lossouarn L (1994) Normal and pathological expres¬sion of GFAP promoter elements in transgenic mice. Glia 12: 281-293.
• García-Tovar CG, Pérez A, Luna J, Mena R, Osorio B, Alemán V (2001) Biochemical and histochemical analy¬sis of 71 kDa dystrophin isoform (Dp71f) in rat brain. Acta Histochem 103: 209-224.
• Glud AN, Hedegaard C, Nielsen MS, Soorensen JC, Bendixen C, Jensen PH, Mogensen PH, Larsen K, Bjarkam CR (2011) Direct MRI-guided stereotaxic viral mediated gene transfer of alpha-synuclein in the Göttingen minipig CNS. Acta Neurobiol Exp (Warsz)71: 508-518.
• Golbe LI (1991) Young-onset Parkinson's disease: a clinical review. Neurology 41: 168-173.
• Guerrero-Cázares H, Alatorre-Carranza MP, Delgado-Rizo V, Duenas-Jiménez JM, Mendoza-Magana ML, Morales- Villagran A , Ramirez-Herrera MA,Guerrero-Hernández A, Segovia J, Duenas-Jimenez SH (2007) Dopamine release modifies intracellular calcium in tyrosine hydrox- ylase-transfected C6 cells. Brain Res Bull 74: 113-118.
• Hadj Tahar A, Grégoire L, Darré A, Bélanger N, Meltzer L, Bédard PJ (2004) Effect of a selective glutamate antago¬nist on L-dopa-induced dyskinesias in drug-naive par¬kinsonian monkeys. Neurobiol Dis 15: 171-176.
• Johnson WB, Rupe MD, Rockenstein EM, Price J, Sarty VP, Verderber LC (1995) Indicator expression directed by regulatory sequences of the glial fibrillary acidic pro¬tein (GFAP) gene: in vivo comparison of distinct GFAP- LacZ transgenes. Glia 13: 174-184.
• Juorio AV, Li XM, Walz W, Paterson IA (1993) Decarboxylation of L-dopa by cultured mouse astro¬cytes. Brain Res 626: 306-309.
• Langston JW, Ballard PA, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980.
• Langston JW, Forno LS, Robert CS, Irwin I (1984) Selective nigral toxicity after systemic administration of 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 292: 390-394.
• Le W, Appel SH (2004) Mutant genes responsible for Parkinson's disease. Curr Opin Pharmacol 4: 79-84.
• Leone P, McPhee WJ, Janson CG, Davidson BL, Freese A, During MJ (2000) Multi-site partitioned delivery of human tyrosine hydroxylase gene with phenotypic recov¬ery in Parkinsonian rats. Neuroreport 11: 1145-1151.
• Luquin MR, Montoro RJ, Guillen J, Saldise L, Insausti R, Del Río J (1999) Recovery of Chronic Parkinsonian Monkeys by Autotransplants of Carotid Body Cell Aggregates into Putamen. Neuron 22: 743-750.
• Markiewicz I, Lukomska B (2006) The role of astrocytes in the physiology and pathology of the central nervous sys¬tem. Acta Neurobiol Exp (Warsz) 66: 343-358.
• Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, Kawasaki K, Ono F (2002) Behavioral recovery in a primate model of Parkinson's disease by triple transduc- tion of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 13: 345-354.
• Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G (1989) Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 39: 11-19.
• Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76: 1265-1274.
• Schrag A, Ben Shlomo Y, Brown R, Marsden CD, Quinn N (1998) Young-onset Parkinson's disease revisted-clinical features, natural history, and mortality. Mov Disord 13: 885-894.
• Segovia J, Vergara P, Brenner M (1998a) Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimen¬tal parkinsonism. Gene Ther 5: 1650-1655.
• Segovia J, Vergara P, Brenner M (1998b) Differentiation- dependent expression of transgenes in engineered astro¬cyte cell lines. Neurosci Lett 242: 172-176.
• Segovia J (2002) Gene therapy for Parkinson's disease: cur¬rent status and future potential. Am J Pharmacogenomics 2: 135-146.
• Shen Y, Muramatsu SI, Ikeguchi K, Fujimoto KI, Fan DS, Ogawa M (2000) Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aro- matic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 11: 1509-1519.
• Taylor JR, Elsworth JD, Sladek JRJr, Collier TJ, Roth RH, Redmond DEJr (1995) Sham surgery does not ameliorate MPTP-induced behavioral deficits in monkeys. Cell transplant 4: 13-26.
• Taylor JR, Elsworth JD, Roth RH, Sladek JRJr, Redmond DEJr (1997) Severe long-term 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience 81: 745-755.
• Trejo F, Vergara P, Brenner M, Segovia J (1999a) Biosynthetic capacity of C6 cells engineered with a glial fibrillary acidic protein-tyrosine hydroxylase transgene. Med Sci Res 27: 423-425.
• Trejo F, Vergara P, Brenner M, Segovia J (1999b) Gene therapy in a rodent model of Parkinson's disease using differentiated C6 cells expressing a GFAP-tyrosine hydroxylase transgene. Life Sci 65: 483-491.
• Tsai MJ, Lee EHY (1996) Characterization of L-dopa trans¬port in cultures rat and mouse astrocytes. J Neurosci Res 43: 490-495.
• Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE (2006) Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmstead country, Minnesota, 1976-1990. Arch Neurol 63: 205-209.
• Yokoyama H, Kuroiwa H, Kasahara J, Araki T (2011) Neuropharmacological approach against MPTP (1-meth- yl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease. Acta Neurobiol Exp (Warsz) 71: 269-280.

Uwagi

Rekord w opracowaniu